Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT03593317
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT03593317
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT03593317. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-20 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
- Acronym
- BRAVE
- Condition
- Arrhythmogenic Right Ventricular Dysplasia
- Intervention (Drug)
- Spironolactone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hospices Civils de Lyon
Record details
- Record id
cardio:ct-nct03593317- Content hash
6ad1199ac2d00f4aefa7c61cb9ebdc8669137de60e0dc86d240fbd616b65cda0